Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study

Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study

Background: To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure with reduced ejection fraction in a real-life setting. Methods: In Prospective, Multicenter, Open Label, Post-A...

Full description

Bibliographic Details
Main Authors: Haissam Haddad, MD, FRCPC, Sebastien Bergeron, MD, FRCPC, Andrew Ignaszewski, MD, FRCPC, Gregory Searles, MD, FRCPC, Driss Rochdi, PhD, Priyanka Dhage, MStat, Natacha Bastien, PhD
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:CJC Open
Online Access:http://www.sciencedirect.com/science/article/pii/S2589790X20300470

Similar Items

Similar Items